Navigation Links
Epizyme Granted First Patent Covering Personalized Therapeutic Drug Candidate E7438
Date:3/22/2013

CAMBRIDGE, Mass., March 22, 2013 /PRNewswire-USNewswire/ -- Epizyme, Inc., a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that it has received a Notice of Issuance from the U.S. Patent and Trademark Office (USPTO) for its patent application entitled "ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS", U.S. Patent No.: 8,410,088. The USPTO granted claims covering the novel small molecule EZH2 inhibitor EPZ-6438 (E7438), a drug candidate for a genetically defined type of non-Hodgkin lymphomas. The patent issuance marks Epizyme's first claims covering this chemical matter.

Epizyme is developing EPZ-6438 (E7438) in partnership with Eisai Co., Ltd. In March 2011, the two companies announced a worldwide partnership to discover, develop and commercialize therapeutics targeting EZH2, with Epizyme retaining an option to co-commercialize, co-develop and share profits for this program with Eisai in the United States.

About Epizyme, Inc.

Epizyme is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers. Epizyme has built a proprietary product platform that we use to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing). To date, Epizyme has entered into therapeutic collaborations with Celgene, Eisai and GSK that have provided it with approximately $120 million in non-equity funding through December 31, 2012. 

For more information, visit http://www.epizyme.com.


'/>"/>
SOURCE Epizyme
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. NanoLogix Instructs Third-Party to Prepare US FDA Submittals and is Granted US and Chinese Patents
2. Ultragenyx Granted Orphan Drug Designation for UX003 for the Treatment of Mucopolysaccharidosis Type 7 (MPS 7)
3. CE Mark Granted for Wound Spray Based on Sangui Patent
4. Butamax Granted Core Patent for Making Biobutanol and Distillers Grains; Offers Producers Efficient, Low-Cost Production of Biobutanol
5. Oramed Pharmaceuticals Granted 2nd Patent in New Zealand; 3rd Patent for Core Technology on Oral Delivery of Proteins
6. ERT Granted Patents on Clinical Trial Participant Compliance
7. Revolutionary Tetrapod Quantum Dot Synthesis US Patent Granted
8. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
9. Avaxia Biologics, Inc. Raises $2.2 Million in First Closing of Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
10. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
11. Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in The Bioscience Industry to Its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... , Oct. 20, 2014 Asterias Biotherapeutics, ... Company has signed a Notice of Grant Award ... (CIRM), effective October 1, 2014.  The NGA provides ... and the release of additional grant funds pursuant ... award for clinical development of Asterias, product, AST-OPC1. ...
(Date:10/20/2014)... PureTech , a science and technology development ... today the closing of a $55 million growth ... a $120 Billion group of funds. The funding ... forward and to advance new healthcare related products ... really go for the big ideas that can ...
(Date:10/19/2014)... 19, 2014 The Latin American hardware ... in Latin America with analysis and forecast of revenue. ... and is expected to reach $2,366.8 million by 2018, ... , Browse through the TOC of the Latin American ... the in-depth analysis provided. It also provides a glimpse ...
(Date:10/19/2014)... The Asian Automatic patient billing report defines and segments ... revenue. The Automatic patient billing market in Asia is ... at a developing CAGR of 7.2% from 2013 to ... Automatic patient billing market, to get an idea of ... of the segmentation of this market in the same ...
Breaking Biology Technology:Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 3
... , Carsten-Peter Carstens Anna Waesche ,Stratagene , ... ,BL21-Gold cells * called the BL21-CodonPlus ... E. coli argU,ileY, and leuW tRNA genes. This modification ... to express in conventional E. coli,hosts due to the ...
... PCR mutagenesis kit produces a unique , mutational spectrum , ... , , ... Stratagene , , , ... The , GeneMorph PCR , mutagenesis kit ...
... precast gels* eliminate the need to manually pour gels, ... means no more gels,lost to bubbles or leaking.All CastAway ... 60 days from the date of manufacture, with no,detectable ... 32 Preformed Wells , Stratagene adds a new 6% ...
Cached Biology Technology:Codon Bias-Adjusted BL21 Derivatives for Protein Expression 2Codon Bias-Adjusted BL21 Derivatives for Protein Expression 3Codon Bias-Adjusted BL21 Derivatives for Protein Expression 4Codon Bias-Adjusted BL21 Derivatives for Protein Expression 5Codon Bias-Adjusted BL21 Derivatives for Protein Expression 6Codon Bias-Adjusted BL21 Derivatives for Protein Expression 7Randomize Gene Sequences with New PCR Mutagenesis Kit 2Randomize Gene Sequences with New PCR Mutagenesis Kit 3Randomize Gene Sequences with New PCR Mutagenesis Kit 4Randomize Gene Sequences with New PCR Mutagenesis Kit 5Randomize Gene Sequences with New PCR Mutagenesis Kit 6Randomize Gene Sequences with New PCR Mutagenesis Kit 7Randomize Gene Sequences with New PCR Mutagenesis Kit 8Randomize Gene Sequences with New PCR Mutagenesis Kit 9Randomize Gene Sequences with New PCR Mutagenesis Kit 10Randomize Gene Sequences with New PCR Mutagenesis Kit 11Four New CastAway Precast Gels 2
(Date:10/14/2014)... in Cancer Research shows SIRT6—a protein known ... promote the development of skin cancers by turning on ... sun-damaged skin cells. , Previously considered protective, SIRT6 is ... that help regulate genomic stability and prevent some of ... DNA damage, which can lead to cancer. This study, ...
(Date:10/14/2014)... a new kind of stem cell that can become either ... vessels, according to a study published today in the journal ... cell type contradicts current theory on how organs arise from ... origins of, and future treatment for, liver cancer., Thanks to ... complex being made up of more than 200 cell types. ...
(Date:10/14/2014)... week, an international team of researchers, led by the ... the journal Nature Genetics a brief genomic ... varieties of the tomato plant. , The C.M. Rick ... important role in this study by providing seed of ... This study, which builds on the first tomato genome ...
Breaking Biology News(10 mins):Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 3
... the Center for Integrated Manufacturing Studies at Rochester Institute ... which blends 20 percent ethanol with gasoline, reduces the ... with traditional gasoline or E10 blends. In addition, the ... or maintenance in conventional internal combustion engines. The ...
... have identified some two million species, where can you ... that unites them all? A vastly improved database gives ... evolutionary relationships among living things. TreeBASE ... study evolutionary trees was first developed in the ...
... of a chemical family they hope will lead to ... specifically against a childhood tumor, according to research led ... chemical is the first small-molecule inhibitor to target the ... childhood eye tumor retinoblastoma as well as certain cases ...
Cached Biology News:E20 fuel reduces carbon monoxide and hydrocarbon emissions in automobiles 2Database gives access to the latest findings about the tree of life 2Database gives access to the latest findings about the tree of life 3Advances reported in quest for drugs targeting childhood cancer 2
... Super-Sensitive, Super-Dark, Super-Small! ... with the ChemiDoc-It Imaging System. High-sensitivity ... produces low-background noise and wide dynamic ... a short exposure time. The light-tight ...
Mouse monoclonal [X223] to Lamin B1 + B2 - Nuclear Envelope Marker ( Abpromise for all tested applications). entrezGeneID: 4001 SwissProtID: P20700...
... Evidence Based Oligonucleotide) Genome Set and MEEBO ... Set contain a collection of open source ... exons, allowing interrogation of thousands of genes. ... Stanford University and UCSF, the sets enable ...
odz, odd Oz/ten-m homolog 1 [Source:RefSeq_peptide;Acc:NP_055068] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Biology Products: